Treatment of malignant gliomas in adults with BCNU plus metronidazole


Twenty-six adult patients with astrocytomas were treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) 180–240 mg/m2 1.V. every 6–9 weeks, with metronidazole 1.5 g/m2 p. o. 12 h and 1 h before BCNU and again 6 h and 24 h after BCNU. Of twenty-two evaluable patients, 9 (41%) responded with evidence of reduced tumor size on CT scan, 3 (14%) stabilized and 10 (45%) failed. Patients with no prior chemotherapy or radiotherapy, good performance. status, low grade tumors, and age ⩽ 50 years had the highest response rates, although differences were not statistically significant. Median survival and duration of response have not been reached with a median follow-up time of ten months. Hematological toxicity was dose-limiting and was probably not augmented by the metronidazole. There was one death from infection that was possibly drug-related. Gastrointestinal toxicity was substantial, and was probably increased by the metronidazole. While the combination of BCNU and metronidazole were tolerable, the response rate seen was no higher than that noted for BCNU alone, and further studies using this dose-schedule are not recommended in astrocytomas.

DOI: 10.1007/BF00165158

2 Figures and Tables


Citations per Year

452 Citations

Semantic Scholar estimates that this publication has 452 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Stewart1984TreatmentOM, title={Treatment of malignant gliomas in adults with BCNU plus metronidazole}, author={David J. Stewart and Brien C. Benoit and Michael T. Richard and Herman Hugenholtz and Jean M Dennery and Neville Russell and Eric D. Peterson and Zvonimir Grahovac and Garry Belanger and Jean Alfred Maroun and V A Linda Young}, journal={Journal of Neuro-Oncology}, year={1984}, volume={2}, pages={53-58} }